董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Quang X. Pham | 男 | Chairman of the Board,Chief Executive Officer and Director | 61 | 190.97万美元 | 33.08 | 2026-09-24 |
| Glynn Wilson | 男 | Independent Director | 78 | 31.01万美元 | 3.13 | 2026-09-24 |
| Lee Golden | 男 | Independent Director | 59 | 3.31万美元 | 0.17 | 2026-09-24 |
| John R. Murphy | 男 | Independent Director | 75 | 31.38万美元 | 7.43 | 2026-09-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Quang X. Pham | 男 | Chairman of the Board,Chief Executive Officer and Director | 61 | 190.97万美元 | 33.08 | 2026-09-24 |
| Jeffrey Cole | 男 | Chief Operating Officer | 58 | 72.63万美元 | 未持股 | 2026-09-24 |
| John P. Sharp | 男 | Interim Chief Financial Officer | 61 | 未披露 | 未持股 | 2026-09-24 |
董事简历
中英对照 | 中文 | 英文- Quang X. Pham
-
Quang X.Pham自2022年组建Cadrenal Therapeutics, Inc.公司以来，一直担任该公司的首席执行官，并自2026年5月起至Sharp先生于2026年6月25日获得任命之前，担任Cadrenal Therapeutics, Inc.的临时首席财务官。他此前曾担任Espero BioPharma（“Espero”）的董事长兼首席执行官，该公司也是他创立的，该公司此前推进了tecarfarin，这是一种3期就绪、孤儿设计的血液稀释剂，自2015年3月成立以来一直到2020年7月，当时为债权人的利益向特拉华州衡平法院提交了转让申请，寻求转让Espero的资产。在他的带领下，Cadrenal还获得了用于冠状动脉搭桥术（CABG）2期的速效因子XIA抗凝剂弗如先和用于治疗肝素诱导的血小板减少症（HIT）的12LOX抑制剂（2期完全）VLX1005。在Espero之前，他创立并担任Lathian Systems的董事长兼首席执行官，这是一家由风险投资支持的数字和数据库营销公司，服务于制药行业，直到被D & R Communications收购。范先生毕业于加州大学洛杉矶分校。他是安永年度企业家奖、BioFlorida年度高管奖的获得者，也是畅销书作家。他还在两次海外冲突中担任美国海军陆战队飞行员。
Quang X. Pham has served as Cadrenal Therapeutics, Inc.'s Chief Executive Officer since he formed the Company in 2022 and served as Cadrenal Therapeutics, Inc.'s Interim Chief Financial Officer from May 2026 until the appointment of Mr. Sharp on June 25, 2026. He previously served as Chairman & CEO of Espero BioPharma ("Espero"), which he also founded, and which previously advanced tecarfarin, a Phase 3 ready, orphan designed blood thinner, since its formation in March 2015 until July 2020, at which time a petition for assignment for the benefit of creditors was filed in the Delaware Chancery Court, seeking an assignment of Espero's assets. Under his leadership, Cadrenal has also acquired frunexian, a fast acting Factor XIa anticoagulant in Phase 2 for coronary artery bypass grafting (CABG), and VLX 1005, a 12 LOX inhibitor (Phase 2 complete) for the treatment of heparin induced thrombocytopenia (HIT). Prior to Espero, he founded and served as Chairman and CEO of Lathian Systems, a venture backed digital and database marketing company serving the pharmaceutical industry until it was acquired by D&R Communications. Mr. Pham is a graduate of UCLA. He is a recipient of the EY Entrepreneur of the Year, BioFlorida's Executive of the Year Awards, and a bestselling author. He also served as a U.S. Marine Corps aviator in two overseas conflicts. - Quang X.Pham自2022年组建Cadrenal Therapeutics, Inc.公司以来，一直担任该公司的首席执行官，并自2026年5月起至Sharp先生于2026年6月25日获得任命之前，担任Cadrenal Therapeutics, Inc.的临时首席财务官。他此前曾担任Espero BioPharma（“Espero”）的董事长兼首席执行官，该公司也是他创立的，该公司此前推进了tecarfarin，这是一种3期就绪、孤儿设计的血液稀释剂，自2015年3月成立以来一直到2020年7月，当时为债权人的利益向特拉华州衡平法院提交了转让申请，寻求转让Espero的资产。在他的带领下，Cadrenal还获得了用于冠状动脉搭桥术（CABG）2期的速效因子XIA抗凝剂弗如先和用于治疗肝素诱导的血小板减少症（HIT）的12LOX抑制剂（2期完全）VLX1005。在Espero之前，他创立并担任Lathian Systems的董事长兼首席执行官，这是一家由风险投资支持的数字和数据库营销公司，服务于制药行业，直到被D & R Communications收购。范先生毕业于加州大学洛杉矶分校。他是安永年度企业家奖、BioFlorida年度高管奖的获得者，也是畅销书作家。他还在两次海外冲突中担任美国海军陆战队飞行员。
- Quang X. Pham has served as Cadrenal Therapeutics, Inc.'s Chief Executive Officer since he formed the Company in 2022 and served as Cadrenal Therapeutics, Inc.'s Interim Chief Financial Officer from May 2026 until the appointment of Mr. Sharp on June 25, 2026. He previously served as Chairman & CEO of Espero BioPharma ("Espero"), which he also founded, and which previously advanced tecarfarin, a Phase 3 ready, orphan designed blood thinner, since its formation in March 2015 until July 2020, at which time a petition for assignment for the benefit of creditors was filed in the Delaware Chancery Court, seeking an assignment of Espero's assets. Under his leadership, Cadrenal has also acquired frunexian, a fast acting Factor XIa anticoagulant in Phase 2 for coronary artery bypass grafting (CABG), and VLX 1005, a 12 LOX inhibitor (Phase 2 complete) for the treatment of heparin induced thrombocytopenia (HIT). Prior to Espero, he founded and served as Chairman and CEO of Lathian Systems, a venture backed digital and database marketing company serving the pharmaceutical industry until it was acquired by D&R Communications. Mr. Pham is a graduate of UCLA. He is a recipient of the EY Entrepreneur of the Year, BioFlorida's Executive of the Year Awards, and a bestselling author. He also served as a U.S. Marine Corps aviator in two overseas conflicts.
- Glynn Wilson
-
Glynn Wilson自2023年1月起在Cadrenal Therapeutics, Inc.董事会任职。现任Caring Brands，Inc.首席执行官兼董事。自2018年11月起担任Jupiter Wellness, Inc.（“Jupiter”）董事会成员，自2019年10月起担任董事长。威尔逊博士还自2021年4月起担任Jupiter的首席科学官，并于2019年10月至2021年7月担任其研发主管。Wilson博士此前曾于2005年2月至2018年10月担任TapImmune，Inc.的董事，并于2009年7月至2017年9月担任首席执行官。Wilson博士还曾于2005年6月1日至2006年3月13日担任Auriga Laboratories，Inc.总裁，并于2016年3月13日至2006年8月25日担任首席科学官。他于1994年至1997年担任Tacora Corporation的首席科学官，并于1997年至1998年担任Access Pharmaceuticals的研发副总裁。Wilson博士于1984 – 1989年在Ciba Geigy Pharmaceuticals担任高级药物递送方面的细胞和分子生物学研究领域负责人，并于1989至1994年在SmithKline Beecham担任药物递送方面的全球负责人。他是纽约洛克菲勒大学的教员，在诺贝尔奖获得者桑福德·摩尔和威廉·斯坦的实验室，从1974年到1979年。威尔逊博士是药物递送系统开发领域公认的领导者，参与了从概念到商业化的主导产品和技术。威尔逊博士拥有生物化学博士学位，曾在纽约洛克菲勒大学进行医学研究。
Glynn Wilson has served on Cadrenal Therapeutics, Inc.'s Board of Directors since January 2023. He is currently Chief Executive Officer and Director of Caring Brands, Inc. He was on the Board of Directors of Jupiter Wellness, Inc. ("Jupiter") since November 2018, serving as Chairman since October 2019. Dr. Wilson also served as Jupiter's Chief Scientific Officer since April 2021 and served as its Head of Research and Development from October 2019 to July 2021. Dr. Wilson previously served as a Director of TapImmune, Inc. from February 2005 until October 2018 and as Chief Executive Officer from July 2009 through September 2017. Dr. Wilson also served as President of Auriga Laboratories, Inc. from June 1, 2005 through March 13, 2006, and as Chief Scientific Officer from March 13, 2016 through August 25, 2006. He was the Chief Scientific Officer at Tacora Corporation from 1994 to 1997 and was the Vice President, R&D, at Access Pharmaceuticals from 1997 to 1998. Dr. Wilson was Research Area Head, Cell and Molecular Biology in Advanced Drug Delivery at Ciba Geigy Pharmaceuticals from 1984 – 1989 and Worldwide Head of Drug Delivery at SmithKline Beecham from 1989 to 1994. He was a faculty member at Rockefeller University, New York, in the laboratory of the Nobel Laureates, Sanford Moore and William Stein, from 1974 to 1979. Dr. Wilson is a recognized leader in the development of drug delivery systems and has been involved in taking lead products & technologies from concept to commercialization. Dr. Wilson has a Ph.D. in Biochemistry and conducted medical research at The Rockefeller University, New York. - Glynn Wilson自2023年1月起在Cadrenal Therapeutics, Inc.董事会任职。现任Caring Brands，Inc.首席执行官兼董事。自2018年11月起担任Jupiter Wellness, Inc.（“Jupiter”）董事会成员，自2019年10月起担任董事长。威尔逊博士还自2021年4月起担任Jupiter的首席科学官，并于2019年10月至2021年7月担任其研发主管。Wilson博士此前曾于2005年2月至2018年10月担任TapImmune，Inc.的董事，并于2009年7月至2017年9月担任首席执行官。Wilson博士还曾于2005年6月1日至2006年3月13日担任Auriga Laboratories，Inc.总裁，并于2016年3月13日至2006年8月25日担任首席科学官。他于1994年至1997年担任Tacora Corporation的首席科学官，并于1997年至1998年担任Access Pharmaceuticals的研发副总裁。Wilson博士于1984 – 1989年在Ciba Geigy Pharmaceuticals担任高级药物递送方面的细胞和分子生物学研究领域负责人，并于1989至1994年在SmithKline Beecham担任药物递送方面的全球负责人。他是纽约洛克菲勒大学的教员，在诺贝尔奖获得者桑福德·摩尔和威廉·斯坦的实验室，从1974年到1979年。威尔逊博士是药物递送系统开发领域公认的领导者，参与了从概念到商业化的主导产品和技术。威尔逊博士拥有生物化学博士学位，曾在纽约洛克菲勒大学进行医学研究。
- Glynn Wilson has served on Cadrenal Therapeutics, Inc.'s Board of Directors since January 2023. He is currently Chief Executive Officer and Director of Caring Brands, Inc. He was on the Board of Directors of Jupiter Wellness, Inc. ("Jupiter") since November 2018, serving as Chairman since October 2019. Dr. Wilson also served as Jupiter's Chief Scientific Officer since April 2021 and served as its Head of Research and Development from October 2019 to July 2021. Dr. Wilson previously served as a Director of TapImmune, Inc. from February 2005 until October 2018 and as Chief Executive Officer from July 2009 through September 2017. Dr. Wilson also served as President of Auriga Laboratories, Inc. from June 1, 2005 through March 13, 2006, and as Chief Scientific Officer from March 13, 2016 through August 25, 2006. He was the Chief Scientific Officer at Tacora Corporation from 1994 to 1997 and was the Vice President, R&D, at Access Pharmaceuticals from 1997 to 1998. Dr. Wilson was Research Area Head, Cell and Molecular Biology in Advanced Drug Delivery at Ciba Geigy Pharmaceuticals from 1984 – 1989 and Worldwide Head of Drug Delivery at SmithKline Beecham from 1989 to 1994. He was a faculty member at Rockefeller University, New York, in the laboratory of the Nobel Laureates, Sanford Moore and William Stein, from 1974 to 1979. Dr. Wilson is a recognized leader in the development of drug delivery systems and has been involved in taking lead products & technologies from concept to commercialization. Dr. Wilson has a Ph.D. in Biochemistry and conducted medical research at The Rockefeller University, New York.
- Lee Golden
-
Lee Golden目前担任PTC Therapeutics，Inc.的执行副总裁兼首席医疗官，PTC Therapeutics，Inc.是一家在纳斯达克上市的公司，在该公司领导广泛的罕见病管道的全球临床开发。在加入PTC之前，Golden博士曾在Espero BioPharma，Inc.担任首席医疗官，该公司是一家处于发展阶段的心血管制药公司，专注于为血栓形成和心律控制方面未满足的需求开发药物，并在Gemphire Therapeutics，Inc.担任首席医疗官。他还担任凝血科学有限责任公司顾问委员会主席。此前，Golden博士曾在辉瑞、Actelion、卫材、Mesoblast等公司担任高级职务，长期专注于心血管和血液学药物开发。Golden博士拥有超过25年的行业经验，职责不断增加，管理负责创建和部署战略和临床开发计划的全球、跨职能团队。他在多个治疗领域和孤儿疾病方面拥有丰富的经验。Golden博士获得了密歇根大学的学士学位和纽约大学医学院的医学博士学位，并在那里完成了他的内科住院医师实习。随后，他在迈阿密大学完成了心脏病学研究金，并在乔治华盛顿大学医院完成了介入心脏病学，在那里他还担任了兼职讲师。
Lee Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc., a Nasdaq listed company, where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development stage cardiovascular pharmaceutical company focused on developing drugs for unmet needs in thrombosis and cardiac rhythm control, and as Chief Medical Officer at Gemphire Therapeutics, Inc. He also serves as Chairman of the Advisory Board for Coagulation Sciences LLC. Previously, Dr. Golden held senior roles at Pfizer, Actelion, Eisai, Mesoblast, and others, with a long standing focus on cardiovascular and hematologic drug development. Dr. Golden has more than 25 years of industry experience, with increasing responsibilities, managing global, cross functional teams responsible for creating and deploying strategic and clinical development plans. He has extensive experience across multiple therapeutic areas and with orphan diseases. Dr. Golden received a B.S. from the University of Michigan and an MD from New York University School of Medicine, where he also completed his Internal Medicine residency. He then completed Fellowships in Cardiology at the University of Miami and Interventional Cardiology at George Washington University Hospital, where he also served as an adjunct instructor. - Lee Golden目前担任PTC Therapeutics，Inc.的执行副总裁兼首席医疗官，PTC Therapeutics，Inc.是一家在纳斯达克上市的公司，在该公司领导广泛的罕见病管道的全球临床开发。在加入PTC之前，Golden博士曾在Espero BioPharma，Inc.担任首席医疗官，该公司是一家处于发展阶段的心血管制药公司，专注于为血栓形成和心律控制方面未满足的需求开发药物，并在Gemphire Therapeutics，Inc.担任首席医疗官。他还担任凝血科学有限责任公司顾问委员会主席。此前，Golden博士曾在辉瑞、Actelion、卫材、Mesoblast等公司担任高级职务，长期专注于心血管和血液学药物开发。Golden博士拥有超过25年的行业经验，职责不断增加，管理负责创建和部署战略和临床开发计划的全球、跨职能团队。他在多个治疗领域和孤儿疾病方面拥有丰富的经验。Golden博士获得了密歇根大学的学士学位和纽约大学医学院的医学博士学位，并在那里完成了他的内科住院医师实习。随后，他在迈阿密大学完成了心脏病学研究金，并在乔治华盛顿大学医院完成了介入心脏病学，在那里他还担任了兼职讲师。
- Lee Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc., a Nasdaq listed company, where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development stage cardiovascular pharmaceutical company focused on developing drugs for unmet needs in thrombosis and cardiac rhythm control, and as Chief Medical Officer at Gemphire Therapeutics, Inc. He also serves as Chairman of the Advisory Board for Coagulation Sciences LLC. Previously, Dr. Golden held senior roles at Pfizer, Actelion, Eisai, Mesoblast, and others, with a long standing focus on cardiovascular and hematologic drug development. Dr. Golden has more than 25 years of industry experience, with increasing responsibilities, managing global, cross functional teams responsible for creating and deploying strategic and clinical development plans. He has extensive experience across multiple therapeutic areas and with orphan diseases. Dr. Golden received a B.S. from the University of Michigan and an MD from New York University School of Medicine, where he also completed his Internal Medicine residency. He then completed Fellowships in Cardiology at the University of Miami and Interventional Cardiology at George Washington University Hospital, where he also served as an adjunct instructor.
- John R. Murphy
-
John R. Murphy自2013年1月担任高峰会议材料有限公司临时首席财务官。他也是其审计委员会董事及主席。他还担任DJO全球董事及审计委员会主席。在2012年，他担任公司董事，审计委员会和Graham包装公司的专门委员会成员，直到当年9月该公司被出售。从2009年至2010年，他领导公司的财务重组，直到2008年，他担任Smurfit石集装箱总公司的高级副总裁兼财务总监，该公司是纸板及纸制包装产品的领先制造商。他是雅固拉公司总裁兼首席执行官和董事会成员，雅固拉公司在2009年10月申请破产，在2010年被并购。2007年1月至2007年10月，他曾担任雅固拉公司总裁兼首席营运官，2006年2月至2006年12月他担任总裁兼财务总监，从1998年3月至2006年1月，他担任雅固拉的执行副总裁兼财务总监。他持有会计宾州州立大学理科学士学位，和罗拉多大学工商管理科硕士学位，他还是一名注册会计师。
John R. Murphy has served on Cadrenal Therapeutics, Inc.'s Board of Directors since January 2023. Since 2003, John R. Murphy has served on the Board of Directors of O'Reilly Automotive, Inc., where he served as Chairman of the Audit Committee from 2003 until 2019. Currently, he serves on the Audit Committee and Human Capital and Compensation Committee (Chair). Mr. Murphy also served on the Board of Directors of Summit Materials, Inc. from 2012 to 2024, where he was the Chair of the Audit Committee. Previously he served as a Director, Audit Committee Chairman, and Member of the Nominating and Governance Committee of Apria, Inc. ("Apria") from August 2019 until April 2022. He also served on the Board of Directors of Alight Solutions LLC and was the Audit Committee Chairman from February 2020 until May 2022 and DJO Global, Inc. from 2012 until 2019. Mr. Murphy also previously served on the Board of Directors of Graham Packaging, Inc. and Accuride Corporation, Inc. He previously served as Interim Chief Financial Officer of Summit Materials, Inc. in 2013, Senior Vice President and Chief Financial Officer of Smurfit Stone Container Corporation from 2009 to 2010, and Chief Financial Officer, then President and Chief Operating Officer, then President and Chief Executive Officer with Accuride Corporation, Inc. from 1998 to 2008. Mr. Murphy holds a Bachelor of Science in Accounting from Pennsylvania State University and a Master of Business Administration from the University of Colorado, and is a Certified Public Accountant. - John R. Murphy自2013年1月担任高峰会议材料有限公司临时首席财务官。他也是其审计委员会董事及主席。他还担任DJO全球董事及审计委员会主席。在2012年，他担任公司董事，审计委员会和Graham包装公司的专门委员会成员，直到当年9月该公司被出售。从2009年至2010年，他领导公司的财务重组，直到2008年，他担任Smurfit石集装箱总公司的高级副总裁兼财务总监，该公司是纸板及纸制包装产品的领先制造商。他是雅固拉公司总裁兼首席执行官和董事会成员，雅固拉公司在2009年10月申请破产，在2010年被并购。2007年1月至2007年10月，他曾担任雅固拉公司总裁兼首席营运官，2006年2月至2006年12月他担任总裁兼财务总监，从1998年3月至2006年1月，他担任雅固拉的执行副总裁兼财务总监。他持有会计宾州州立大学理科学士学位，和罗拉多大学工商管理科硕士学位，他还是一名注册会计师。
- John R. Murphy has served on Cadrenal Therapeutics, Inc.'s Board of Directors since January 2023. Since 2003, John R. Murphy has served on the Board of Directors of O'Reilly Automotive, Inc., where he served as Chairman of the Audit Committee from 2003 until 2019. Currently, he serves on the Audit Committee and Human Capital and Compensation Committee (Chair). Mr. Murphy also served on the Board of Directors of Summit Materials, Inc. from 2012 to 2024, where he was the Chair of the Audit Committee. Previously he served as a Director, Audit Committee Chairman, and Member of the Nominating and Governance Committee of Apria, Inc. ("Apria") from August 2019 until April 2022. He also served on the Board of Directors of Alight Solutions LLC and was the Audit Committee Chairman from February 2020 until May 2022 and DJO Global, Inc. from 2012 until 2019. Mr. Murphy also previously served on the Board of Directors of Graham Packaging, Inc. and Accuride Corporation, Inc. He previously served as Interim Chief Financial Officer of Summit Materials, Inc. in 2013, Senior Vice President and Chief Financial Officer of Smurfit Stone Container Corporation from 2009 to 2010, and Chief Financial Officer, then President and Chief Operating Officer, then President and Chief Executive Officer with Accuride Corporation, Inc. from 1998 to 2008. Mr. Murphy holds a Bachelor of Science in Accounting from Pennsylvania State University and a Master of Business Administration from the University of Colorado, and is a Certified Public Accountant.
高管简历
中英对照 | 中文 | 英文- Quang X. Pham
Quang X.Pham自2022年组建Cadrenal Therapeutics, Inc.公司以来，一直担任该公司的首席执行官，并自2026年5月起至Sharp先生于2026年6月25日获得任命之前，担任Cadrenal Therapeutics, Inc.的临时首席财务官。他此前曾担任Espero BioPharma（“Espero”）的董事长兼首席执行官，该公司也是他创立的，该公司此前推进了tecarfarin，这是一种3期就绪、孤儿设计的血液稀释剂，自2015年3月成立以来一直到2020年7月，当时为债权人的利益向特拉华州衡平法院提交了转让申请，寻求转让Espero的资产。在他的带领下，Cadrenal还获得了用于冠状动脉搭桥术（CABG）2期的速效因子XIA抗凝剂弗如先和用于治疗肝素诱导的血小板减少症（HIT）的12LOX抑制剂（2期完全）VLX1005。在Espero之前，他创立并担任Lathian Systems的董事长兼首席执行官，这是一家由风险投资支持的数字和数据库营销公司，服务于制药行业，直到被D & R Communications收购。范先生毕业于加州大学洛杉矶分校。他是安永年度企业家奖、BioFlorida年度高管奖的获得者，也是畅销书作家。他还在两次海外冲突中担任美国海军陆战队飞行员。
Quang X. Pham has served as Cadrenal Therapeutics, Inc.'s Chief Executive Officer since he formed the Company in 2022 and served as Cadrenal Therapeutics, Inc.'s Interim Chief Financial Officer from May 2026 until the appointment of Mr. Sharp on June 25, 2026. He previously served as Chairman & CEO of Espero BioPharma ("Espero"), which he also founded, and which previously advanced tecarfarin, a Phase 3 ready, orphan designed blood thinner, since its formation in March 2015 until July 2020, at which time a petition for assignment for the benefit of creditors was filed in the Delaware Chancery Court, seeking an assignment of Espero's assets. Under his leadership, Cadrenal has also acquired frunexian, a fast acting Factor XIa anticoagulant in Phase 2 for coronary artery bypass grafting (CABG), and VLX 1005, a 12 LOX inhibitor (Phase 2 complete) for the treatment of heparin induced thrombocytopenia (HIT). Prior to Espero, he founded and served as Chairman and CEO of Lathian Systems, a venture backed digital and database marketing company serving the pharmaceutical industry until it was acquired by D&R Communications. Mr. Pham is a graduate of UCLA. He is a recipient of the EY Entrepreneur of the Year, BioFlorida's Executive of the Year Awards, and a bestselling author. He also served as a U.S. Marine Corps aviator in two overseas conflicts.- Quang X.Pham自2022年组建Cadrenal Therapeutics, Inc.公司以来，一直担任该公司的首席执行官，并自2026年5月起至Sharp先生于2026年6月25日获得任命之前，担任Cadrenal Therapeutics, Inc.的临时首席财务官。他此前曾担任Espero BioPharma（“Espero”）的董事长兼首席执行官，该公司也是他创立的，该公司此前推进了tecarfarin，这是一种3期就绪、孤儿设计的血液稀释剂，自2015年3月成立以来一直到2020年7月，当时为债权人的利益向特拉华州衡平法院提交了转让申请，寻求转让Espero的资产。在他的带领下，Cadrenal还获得了用于冠状动脉搭桥术（CABG）2期的速效因子XIA抗凝剂弗如先和用于治疗肝素诱导的血小板减少症（HIT）的12LOX抑制剂（2期完全）VLX1005。在Espero之前，他创立并担任Lathian Systems的董事长兼首席执行官，这是一家由风险投资支持的数字和数据库营销公司，服务于制药行业，直到被D & R Communications收购。范先生毕业于加州大学洛杉矶分校。他是安永年度企业家奖、BioFlorida年度高管奖的获得者，也是畅销书作家。他还在两次海外冲突中担任美国海军陆战队飞行员。
- Quang X. Pham has served as Cadrenal Therapeutics, Inc.'s Chief Executive Officer since he formed the Company in 2022 and served as Cadrenal Therapeutics, Inc.'s Interim Chief Financial Officer from May 2026 until the appointment of Mr. Sharp on June 25, 2026. He previously served as Chairman & CEO of Espero BioPharma ("Espero"), which he also founded, and which previously advanced tecarfarin, a Phase 3 ready, orphan designed blood thinner, since its formation in March 2015 until July 2020, at which time a petition for assignment for the benefit of creditors was filed in the Delaware Chancery Court, seeking an assignment of Espero's assets. Under his leadership, Cadrenal has also acquired frunexian, a fast acting Factor XIa anticoagulant in Phase 2 for coronary artery bypass grafting (CABG), and VLX 1005, a 12 LOX inhibitor (Phase 2 complete) for the treatment of heparin induced thrombocytopenia (HIT). Prior to Espero, he founded and served as Chairman and CEO of Lathian Systems, a venture backed digital and database marketing company serving the pharmaceutical industry until it was acquired by D&R Communications. Mr. Pham is a graduate of UCLA. He is a recipient of the EY Entrepreneur of the Year, BioFlorida's Executive of the Year Awards, and a bestselling author. He also served as a U.S. Marine Corps aviator in two overseas conflicts.
- Jeffrey Cole
Jeffrey Cole自2024年2月起担任Cadrenal Therapeutics, Inc.的首席运营官。Cole先生在全球医药制造和商业运营、金融和企业发展方面拥有超过25年的经验。在被任命为首席运营官之前，他于2022年7月开始担任公司顾问。自2010年8月以来，Cole先生担任J. Scott Capital，LLC的负责人，该公司在被任命为首席运营官之前，为包括Cadrenal在内的新兴成长型生命科学组织提供执行和资本资源。2015年3月至2020年7月，担任Espero总裁、首席财务官及联合创始人，并于2016年4月至2018年8月期间担任董事。2010年8月至2015年2月，他担任非处方药营销商和分销商MarcasUSA，LLC的总裁和联合创始人。2008年5月至2010年8月，Cole先生在Legacy Pharmaceuticals International GmbH（一家全球合同制造组织）担任首席财务官，并在其仿制药子公司Solco Healthcare U.S.，Inc.担任创始总裁。从2002年2月至2008年5月，Cole先生在Valeant Pharmaceuticals International，Inc.（现为Bausch Health公司）担任过多个行政职务，包括总经理、企业发展副总裁以及北美地区首席财务官。在进入制药行业之前，Cole先生于2000年1月至2002年1月在技术行业工作。Cole先生还在1994年7月至2000年1月期间担任普华永道财务管理咨询业务的负责人。科尔先生拥有密歇根大学的荣誉MBA学位和南加州大学的会计学学士学位。
Jeffrey Cole has served as Cadrenal Therapeutics, Inc.'s Chief Operating Officer since February 2024. Mr. Cole has over 25 years of experience in global pharmaceutical manufacturing and commercial operations, finance, and corporate development. Prior to his appointment as Chief Operating Officer, he served as a consultant to the Company beginning in July 2022. Since August 2010, Mr. Cole has served as Principal of J. Scott Capital, LLC, a firm that provides executive and capital resources to emerging growth life science organizations, including Cadrenal prior to his appointment as Chief Operating Officer. From March 2015 to July 2020, he served as President, Chief Financial Officer and co founder of Espero, where he also served as a director from April 2016 until August 2018. From August 2010 to February 2015, he served as President and co founder of MarcasUSA, LLC, a marketer and distributor of over the counter pharmaceuticals. From May 2008 to August 2010, Mr. Cole was Chief Financial Officer of Legacy Pharmaceuticals International GmbH, a global contract manufacturing organization, and founding President of its generic pharmaceuticals subsidiary Solco Healthcare U.S., Inc. From February 2002 to May 2008, Mr. Cole held various executive positions at Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies), including General Manager, Vice President of Corporate Development, and Chief Financial Officer for North America. Prior to the pharmaceutical industry, Mr. Cole worked in the technology industry from January 2000 to January 2002. Mr. Cole also served as Principal in the Financial Management Consulting practice at PricewaterhouseCoopers from July 1994 to January 2000. Mr. Cole holds an MBA with honors from the University of Michigan and a BS in accounting from the University of Southern California.- Jeffrey Cole自2024年2月起担任Cadrenal Therapeutics, Inc.的首席运营官。Cole先生在全球医药制造和商业运营、金融和企业发展方面拥有超过25年的经验。在被任命为首席运营官之前，他于2022年7月开始担任公司顾问。自2010年8月以来，Cole先生担任J. Scott Capital，LLC的负责人，该公司在被任命为首席运营官之前，为包括Cadrenal在内的新兴成长型生命科学组织提供执行和资本资源。2015年3月至2020年7月，担任Espero总裁、首席财务官及联合创始人，并于2016年4月至2018年8月期间担任董事。2010年8月至2015年2月，他担任非处方药营销商和分销商MarcasUSA，LLC的总裁和联合创始人。2008年5月至2010年8月，Cole先生在Legacy Pharmaceuticals International GmbH（一家全球合同制造组织）担任首席财务官，并在其仿制药子公司Solco Healthcare U.S.，Inc.担任创始总裁。从2002年2月至2008年5月，Cole先生在Valeant Pharmaceuticals International，Inc.（现为Bausch Health公司）担任过多个行政职务，包括总经理、企业发展副总裁以及北美地区首席财务官。在进入制药行业之前，Cole先生于2000年1月至2002年1月在技术行业工作。Cole先生还在1994年7月至2000年1月期间担任普华永道财务管理咨询业务的负责人。科尔先生拥有密歇根大学的荣誉MBA学位和南加州大学的会计学学士学位。
- Jeffrey Cole has served as Cadrenal Therapeutics, Inc.'s Chief Operating Officer since February 2024. Mr. Cole has over 25 years of experience in global pharmaceutical manufacturing and commercial operations, finance, and corporate development. Prior to his appointment as Chief Operating Officer, he served as a consultant to the Company beginning in July 2022. Since August 2010, Mr. Cole has served as Principal of J. Scott Capital, LLC, a firm that provides executive and capital resources to emerging growth life science organizations, including Cadrenal prior to his appointment as Chief Operating Officer. From March 2015 to July 2020, he served as President, Chief Financial Officer and co founder of Espero, where he also served as a director from April 2016 until August 2018. From August 2010 to February 2015, he served as President and co founder of MarcasUSA, LLC, a marketer and distributor of over the counter pharmaceuticals. From May 2008 to August 2010, Mr. Cole was Chief Financial Officer of Legacy Pharmaceuticals International GmbH, a global contract manufacturing organization, and founding President of its generic pharmaceuticals subsidiary Solco Healthcare U.S., Inc. From February 2002 to May 2008, Mr. Cole held various executive positions at Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies), including General Manager, Vice President of Corporate Development, and Chief Financial Officer for North America. Prior to the pharmaceutical industry, Mr. Cole worked in the technology industry from January 2000 to January 2002. Mr. Cole also served as Principal in the Financial Management Consulting practice at PricewaterhouseCoopers from July 1994 to January 2000. Mr. Cole holds an MBA with honors from the University of Michigan and a BS in accounting from the University of Southern California.
- John P. Sharp
John P. Sharp于2026年3月被任命为公司首席财务官。夏普先生是一位经验丰富的财务主管，在财务和业务规划方面拥有30多年的经验，目前担任Lohman & Associates的高级董事。自2007年4月起，他在多家生物制药公司担任首席财务官。2022年12月至2025年10月，任SANOTEZ Research and Development Corp. 首席财务官。在此之前，Sharp先生为PhaseBio制药，Inc.（丨纳斯达克纳斯达克：PHAS）的首席财务官,2016年4月至2022年11月11日，HUYA Bioscience International，LLC的首席财务官的TERM5首席财务官，2014年3月至2015年12月，Ligand Pharmaceuticals（丨纳斯达克纳斯达克：LGND）的首席财务官的TERM7首席财务官，2007年4月至2014年3月。他还是普华永道会计师事务所（Pricewaterhouse Coopers LLP）的前审计师。夏普先生在圣地亚哥州立大学获得工商管理学士学位，重点是会计学，是加利福尼亚州的一名注册会计师（非在职）。
John P. Sharp was appointed as the Company's Chief Financial Officer in March 2026. Mr. Sharp is a seasoned finance executive with more than 30 years of experience in financial and business planning and currently serves as a Senior Director at Lohman & Associates. Since April 2007, he has served as chief financial officer for several biopharmaceutical companies. From December 2022 to October 2025, he was the Chief Financial Officer for SaNOtize Research and Development Corp. Prior to this, Mr. Sharp was the Chief Financial Officer of PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), from April 2016 to November 11, 2022, the Chief Financial Officer of HUYA Bioscience International, LLC, from March 2014 to December 2015 and the Chief Financial Officer of Ligand Pharmaceuticals (Nasdaq: LGND), from April 2007 to March 2014. He is also a former auditor with Pricewaterhouse Coopers LLP. Mr. Sharp received a BS in business administration with an emphasis in accounting from San Diego State University and is a certified public accountant (inactive) in California.- John P. Sharp于2026年3月被任命为公司首席财务官。夏普先生是一位经验丰富的财务主管，在财务和业务规划方面拥有30多年的经验，目前担任Lohman & Associates的高级董事。自2007年4月起，他在多家生物制药公司担任首席财务官。2022年12月至2025年10月，任SANOTEZ Research and Development Corp. 首席财务官。在此之前，Sharp先生为PhaseBio制药，Inc.（丨纳斯达克纳斯达克：PHAS）的首席财务官,2016年4月至2022年11月11日，HUYA Bioscience International，LLC的首席财务官的TERM5首席财务官，2014年3月至2015年12月，Ligand Pharmaceuticals（丨纳斯达克纳斯达克：LGND）的首席财务官的TERM7首席财务官，2007年4月至2014年3月。他还是普华永道会计师事务所（Pricewaterhouse Coopers LLP）的前审计师。夏普先生在圣地亚哥州立大学获得工商管理学士学位，重点是会计学，是加利福尼亚州的一名注册会计师（非在职）。
- John P. Sharp was appointed as the Company's Chief Financial Officer in March 2026. Mr. Sharp is a seasoned finance executive with more than 30 years of experience in financial and business planning and currently serves as a Senior Director at Lohman & Associates. Since April 2007, he has served as chief financial officer for several biopharmaceutical companies. From December 2022 to October 2025, he was the Chief Financial Officer for SaNOtize Research and Development Corp. Prior to this, Mr. Sharp was the Chief Financial Officer of PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), from April 2016 to November 11, 2022, the Chief Financial Officer of HUYA Bioscience International, LLC, from March 2014 to December 2015 and the Chief Financial Officer of Ligand Pharmaceuticals (Nasdaq: LGND), from April 2007 to March 2014. He is also a former auditor with Pricewaterhouse Coopers LLP. Mr. Sharp received a BS in business administration with an emphasis in accounting from San Diego State University and is a certified public accountant (inactive) in California.